Glaukos Corp (GKOS):企業の製品パイプライン分析2018

◆英語タイトル:Glaukos Corp (GKOS) - Product Pipeline Analysis, 2018 Update
◆商品コード:DATA904C2867
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glaukos Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Glaukos Corp Company Overview 6
Glaukos Corp Company Snapshot 6
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp – Pipeline Analysis Overview 8
Glaukos Corp – Key Facts 8
Glaukos Corp – Major Products and Services 9
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Pipeline Products Overview 15
GTS400 15
GTS400 Product Overview 15
iDose Travoprost Intraocular Implant 16
iDose Travoprost Intraocular Implant Product Overview 16
iDose Travoprost Intraocular Implant Clinical Trial 17
IOP Sensor System 18
IOP Sensor System Product Overview 18
iStent Infinite 19
iStent Infinite Product Overview 19
iStent Infinite Clinical Trial 20
iStent inject Trabecular Micro-Bypass Stent 21
iStent inject Trabecular Micro-Bypass Stent Product Overview 21
iStent inject Trabecular Micro-Bypass Stent Clinical Trial 22
iStent SA 25
iStent SA Product Overview 25
iStent SA Clinical Trial 26
iStent Supra Suprachoroidal Micro-Bypass Stent 30
iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview 30
iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial 31
Glaukos Corp – Key Competitors 34
Glaukos Corp – Key Employees 35
Glaukos Corp – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Glaukos Corp, Recent Developments 37
Jun 25, 2018: Glaukos’ iStent inject micro-bypass device gets FDA approval 37
May 09, 2018: Glaukos Announces First Quarter 2018 Financial Results 37
Apr 14, 2018: IDE Pivotal Trial Results for Glaukos iStent inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery 38
Apr 11, 2018: Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery 39
Feb 28, 2018: Glaukos Reports Fourth Quarter and Full Year 2017 Financial Results 41
Feb 28, 2018: Raysearch Laboratories: First clinic now live with RayCare 42
Feb 27, 2018: Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting 43
Feb 27, 2018: International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients 44
Feb 26, 2018: Apollo Endosurgery Announces First ORBERA U.S. Post-Approval Publication 45
Feb 08, 2018: Glaukos iStent Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study 46
Appendix 48
Methodology 48
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview 6
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Indication 7
Glaukos Corp Ongoing Clinical Trials by Trial Status 7
Glaukos Corp, Key Facts 8
Glaukos Corp, Major Products and Services 9
Glaukos Corp Number of Pipeline Products by Development Stage 10
Glaukos Corp Pipeline Products Summary by Development Stage 11
Glaukos Corp Ongoing Clinical Trials by Trial Status 12
Glaukos Corp Ongoing Clinical Trials Summary 13
GTS400 - Product Status 15
GTS400 - Product Description 15
iDose Travoprost Intraocular Implant - Product Status 16
iDose Travoprost Intraocular Implant - Product Description 16
iDose Travoprost Intraocular Implant - A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients 17
iDose Travoprost Intraocular Implant - Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure 17
IOP Sensor System - Product Status 18
IOP Sensor System - Product Description 18
iStent Infinite - Product Status 19
iStent Infinite - Product Description 19
iStent Infinite - A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients 20
iStent inject Trabecular Micro-Bypass Stent - Product Status 21
iStent inject Trabecular Micro-Bypass Stent - Product Description 21
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 22
iStent inject Trabecular Micro-Bypass Stent - A Prospective Evaluation of the Second Generation iStent Inject in Open-angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized Evaluation of Subjects with Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naive to Medical and Surgical Therapy, Treated with Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% 23
iStent inject Trabecular Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction with Cataract Surgery 24
iStent inject Trabecular Micro-Bypass Stent - A Randomized Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery with Insertion of iStent Inject 24
iStent SA - Product Status 25
iStent SA - Product Description 25
iStent SA - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) 26
iStent SA - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin 27
iStent SA - Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject 27
iStent SA - The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study 28
iStent SA - Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors 28
iStent SA - US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery 29
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Status 30
iStent Supra Suprachoroidal Micro-Bypass Stent - Product Description 30
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg §23.B 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent 31
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent 32
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin 33
iStent Supra Suprachoroidal Micro-Bypass Stent - A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery 33
Glaukos Corp, Key Employees 35
Glaukos Corp, Subsidiaries 36
Glossary 50

List of Figures
Glaukos Corp Pipeline Products by Equipment Type 7
Glaukos Corp Pipeline Products by Development Stage 10
Glaukos Corp Ongoing Clinical Trials by Trial Status 12

★海外企業調査レポート[Glaukos Corp (GKOS):企業の製品パイプライン分析2018]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ohio State University Comprehensive Cancer Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Ohio State University Comprehensive Cancer Center (OSUCCC), a subsidiary of Ohio State University, is a healthcare institute that offers medical and academic education services. The institute provides education, research, and patient care services. Its services comprise cancer diagnosis, tre …
  • ORChem Co., Ltd.:企業のM&A・事業提携・投資動向
    ORChem Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ORChem Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • bioMerieux SA (BIM)-医療機器分野:企業M&A・提携分析
    Summary bioMerieux S.A. (bioMerieux) designs, develops and manufactures diagnostic systems and reagents for physicians and biologists. The company offers diagnostic solutions such as instruments, reagents and software. bioMerieux products are used diagnosing and managing infectious diseases, cardiov …
  • JD Sports Fashion Plc:企業のM&A・事業提携・投資動向
    JD Sports Fashion Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JD Sports Fashion Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • BioView Ltd (BIOV):企業の財務・戦略的SWOT分析
    BioView Ltd (BIOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Regenicin Inc (RGIN):製薬・医療:M&Aディール及び事業提携情報
    Summary Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tiss …
  • juwi AG:企業の戦略的SWOT分析
    juwi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Allied Irish Banks Plc:企業の戦略的SWOT分析
    Allied Irish Banks Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Allied Irish Banks, Plc:戦略・SWOT・企業財務分析
    Allied Irish Banks, Plc - Strategy, SWOT and Corporate Finance Report Summary Allied Irish Banks, Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Public Establishment for Electricity Generation and Transmission Co:企業の戦略的SWOT分析
    Public Establishment for Electricity Generation and Transmission Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key empl …
  • Trinity Industries, Inc.:企業の戦略・SWOT・財務分析
    Trinity Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Trinity Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary OMEICOS Therapeutics GmbH (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The company utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to …
  • Tata Motors Limited:企業の戦略・SWOT・財務情報
    Tata Motors Limited - Strategy, SWOT and Corporate Finance Report Summary Tata Motors Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ATCO Power Ltd:企業の戦略的SWOT分析
    ATCO Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Yokogawa Electric Corp (6841):石油・ガス:M&Aディール及び事業提携情報
    Summary Yokogawa Electric Corp (Yokogawa) is an industrial automation company. It manufactures and supplies products and solutions in measurement, control, and information technologies fields. The company’s product offering include differential pressure/pressure transmitters, flow meters, and proces …
  • Microsoft Corp (MSFT):医療機器:M&Aディール及び事業提携情報
    Summary Microsoft Corporation (Microsoft) is a technology-based company that develops, licenses, and supports software products, services, and devices. The company offers a comprehensive range of operating systems, cross-device productivity applications, server applications, business solution applic …
  • Takuma Co Ltd (6013):企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PT. Indonesia Power:企業の発電所・SWOT分析2018
    PT. Indonesia Power - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Genesis Energy, L.P.:企業の戦略・SWOT・財務情報
    Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report Summary Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Allergan Plc (AGN):医療機器:M&Aディール及び事業提携情報
    Summary Allergan Plc (Allergan) is a specialty pharmaceutical company that develops and sells branded pharmaceuticals, biosimilar and over-the-counter (OTC) pharmaceutical products. It offers products in the areas of eye care, medical aesthetics, dermatology, central nervous system, gastroenterology …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆